๐ฌย #AdvancedScienceย Exciting Breakthrough in Oral Squamous Cell Carcinoma Research! ๐ฌ ๐ง๐ฌOur antibodies played a vital role in an exciting study โ๐๐ข๐ง ๐๐๐ง๐ ๐-๐๐ง๐๐ฎ๐๐๐ ๐๐จ๐ง๐ ๐๐จ๐ง๐๐จ๐๐ข๐ง๐ ๐๐๐ ๐๐๐๐๐๐ ๐๐ซ๐ข๐ฏ๐๐ฌ ๐ญ๐ก๐ ๐๐ซ๐จ๐ ๐ซ๐๐ฌ๐ฌ๐ข๐จ๐ง ๐จ๐ ๐๐ซ๐๐ฅ ๐๐ช๐ฎ๐๐ฆ๐จ๐ฎ๐ฌ ๐๐๐ฅ๐ฅ ๐๐๐ซ๐๐ข๐ง๐จ๐ฆ๐ ๐๐ฒ ๐๐ฅ๐จ๐๐ค๐ข๐ง๐ ๐๐๐๐-๐๐๐๐ข๐๐ญ๐๐ ๐๐๐๐ ๐๐๐ ๐ซ๐๐๐๐ญ๐ข๐จ๐งโ. Researchers identified a highly expressed lncRNA, DUXAP9, in OSCC patients. Elevated levels of DUXAP9 were associated with poor prognosis and aggressive tumor behavior. ๐The study showed that DUXAP9 promotes OSCC cell growth, migration, and invasion, while inhibiting tumor suppression molecules. It also highlighted DUXAP9 as a potential therapeutic target for OSCC. We are proud to have contributed to this research by providing our antibodies. ๐Read the full paper here:ย https://lnkd.in/geRBbu_y #ABclonalย #OSCCResearchย #CancerDiscoveryย #TherapeuticTargetย #Biotechnology
ABclonal Technology (Europe)โs Post
More Relevant Posts
-
Unlocking Research Potential in Precision Medicine and Drug Discovery | Advancing Life Science Innovations Through Meaningful Collaborations
๐ฌ ๐๐ฑ๐๐ข๐ญ๐ข๐ง๐ ๐๐ซ๐๐๐ค๐ญ๐ก๐ซ๐จ๐ฎ๐ ๐ก ๐ข๐ง ๐๐๐ง๐๐๐ซ ๐๐๐ฌ๐๐๐ซ๐๐ก! ๐ ๐ Scientists have made a groundbreaking discovery in the fight against intrahepatic cholangiocarcinoma (ICC), a challenging bile duct malignancy. Researchers identified a novel mechanism involving isocitrate dehydrogenase mutations, SRC kinase activation, and the effectiveness of dasatinib in treating ICC. This promising finding sheds light on potential combination therapies for patients with IDH-mutant ICC. ๐งฌ The study revealed that dasatinib treatment reduced p70 S6 kinase (S6K) and ribosomal protein S6 (S6), leading to significant reductions in cell size and protein synthesis. By uncovering the role of SRC in activating this signaling pathway independent of mTORC1 complex, researchers identified membrane-associated guanylate kinase, WW, and PDZ domain containing 1 (MAGI1) as a key substrate of SRC in IDH-mutant ICC. ๐ Combining dasatinib with the S6K/AKT inhibitor M2698 resulted in increased cell death and improved tumor growth inhibition in mice bearing patient-derived xenografts. This combination therapy approach holds great promise for enhancing treatment outcomes in patients with IDH-mutant ICC.๐ช #CancerResearch #Innovation #ResearchDiscoveries
To view or add a comment, sign in
-
#MilestonesMonday: Can a survival mechanism used by bacteria create a better drug delivery system? ๐ Inspired by a component of bacterial reproduction, a team of CCR researchers created synthetic spores called โSSHELsโ and then successfully tested SSHELs as a drug delivery vehicle. They hope that someday using SSHELs will reduce side effects from some cancer treatments.ย ๐ โก https://lnkd.in/eNVDfDh6 Side effects of some chemotherapy drugs can range from nausea and fatigue to mood changes and nerve problems, as well as damage to healthy cells and organs. โThese side effects are a huge deterrent for people getting chemotherapy,โ says Kumaran S. Ramamurthi, Ph.D., Senior Investigator and Deputy Chief of the Laboratory of Molecular Biology and lead investigator of the study. โOne way to solve this problem is to make sure that chemotherapy drugs reach only the cancer and not surrounding tissue." National Cancer Institute (NCI), National Institutes of Health (NIH): Intramural Research Program (IRP) #CancerResearch #CancerTreatment #Innovation #Medicine
To view or add a comment, sign in
-
-
#Immunotherapy | A #CAR Body Shop ๐ค | Generation of #CARTcells in vivo using #Lentiviral #Vectors displaying a Multi-Domain Fusion Ligand ๐ | Major Advance from Byoung Ryu & Co. at #BLOOD Online Now ๐ | #cancer | Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformative efficacy in treating B-cell malignancies. However, high cost and manufacturing complexities hinder their widespread use. T Here* to overcome these hurdles, Umoja Biopharma researchers have developed the VivoVecTM platform, a lentiviral vector capable of generating CAR T-cells in vivo. They describe the incorporation of T cell activation and costimulatory signals onto the surface of VivoVecTM particles (VVPs) in the form of a multi-domain fusion protein and show enhanced in vivo transduction and improved CAR-T cell antitumor functionality. Furthermore, in the absence of lymphodepleting chemotherapy, administration of VVPs into non-human primates resulted in the robust generation of anti-CD20 CAR T-cells and the complete depletion of B cells for more than 10 weeks. These data validate the VivoVecTM platform in a translationally relevant model and support its transition into human clinical testing, offering a paradigm shift in the field of CAR T-cell therapies. *https://lnkd.in/eNjvUPdX Celentyx Ltd Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady GRAPHICAL ABSTRACT
To view or add a comment, sign in
-
-
This November, capivasertib (TRUQAPยฎ) received approval by the FDA as a medicine for treating estrogen receptor (ER)-positive metastatic breast cancer (MBC) in adults. It acts as an inhibitor of AKT1, AKT2, and AKT3 isoforms of serine/threonine kinase AKT (protein kinase B) that results in inhibiting the phosphorylation of substrates in the AKT signaling pathway. The AKT kinase plays a crucial role in regulating many processes including metabolism, cell survival, growth, and proliferation. Mutations and loss of functions in the AKT pathway are among the most common reasons for breast cancer. Capivasertib contains piperidine-4-amine moiety in its backbone. To support your further research, we have made a set of Building Blocks that contain such cores, which could be a promising starting point in your research projects! https://buff.ly/47UC6wI #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #search #chemicalindustry #science #structures
To view or add a comment, sign in
-
-
Embryo diapause is a unique biological phenomenon as a survival strategy to enhance reproductive fitness in adverse environments. Recent studies indicate that tumor cells also exhibit a similar state when exposed to chemotherapy drugs, but the molecular mechanisms underlying the transition of tumor cells to a diapause-like state still require further investigation. Earlier this year, a collaborative study published in Cell Metabolism (IF 29.0) provided new insights into the non-hereditary mechanisms of chemotherapy resistance. Utilizing transcriptomics, single-cell sequencing, non-targeted metabolomics (technical support from APTBIO), and metabolic flux analysis, researchers revealed that the diapause-like colorectal cancer cells induced by SMC4 attenuation have low proliferation and chemotherapy insensitivity. ๐ https://lnkd.in/g35kChKE #colorectalcancer #transcriptomics #nontargetmetabolomics #metabolomics #SMC4 #diapauselike #DLCC #embryodiapause #chemotherapyresistance
To view or add a comment, sign in
-
-
Gene-modified cell therapy for the treatment of cancer and other diseases is a rapidly growing area of clinical research. The therapeutic use of engineered cells has necessitated the development of novel lab tests for assessing patient safety and efficacy. In this article Dr Chad Galderisi explores how unique applications of tools such PCR and flow cytometry can be used to provide critical and complementary data that is needed to bring new life saving treatment options to patients. https://ow.ly/z15v50PNHMt
To view or add a comment, sign in
-
-
#IHC #antibody #Epcam Epithelial cell adhesion molecule (EpCAM), also known as CD326 among other names, is a transmembrane glycoprotein mediating Ca2+-independent homotypic cellโcell adhesion in epithelia. EpCAM is also involved in cell signaling, migration, proliferation, and differentiation. Additionally, EpCAM has oncogenic potential via its capacity to upregulate c-myc, e-fabp, and cyclins A & E. Since EpCAM is expressed exclusively in epithelia and epithelial-derived neoplasms, EpCAM can be used as diagnostic marker for various cancers. ย EpCAM Recombinant Rabbit mAb(SDT-078-13) Catalog Number: S0B2028 Location: Synthetic Peptide Application: IHC-P; WB; ICC ย Welcome to request free samples: info@starter-bio.com ย Find more: https://lnkd.in/eFZcZtSt #biotech #lifescience #CDx #IVD #cancer #pathology #Immunohistochemistry
To view or add a comment, sign in
-
-
#CancerCell: #Tumor microbiota can produce active metabolites that affect cancer and #immune cell signaling, #metabolism, and #proliferation. The study demonstrated that #lactic acid bacteria in the tumor #microenvironment can alter tumor metabolism and lactate signaling pathways, causing therapeutic resistance. In other words, Lactic acid bacteria could be promising therapeutic targets across cancer types. https://lnkd.in/gtDZtywP For more push, please follow #Twitter: https://lnkd.in/gntQ9qE7 Related Product Recommendation: #Gemcitabine (https://lnkd.in/gGbhxJ7S); #Phytohemagglutinin (https://lnkd.in/gJhds-96); #Hyaluronidase (https://lnkd.in/gjxkkv82); #A83-01 (https://lnkd.in/gQtHZhZf); #Forskolin (https://lnkd.in/gE_WVqZC).
To view or add a comment, sign in
-
-
The objective of this post is to provide a brief explanation on the use of lentiviral vectors for the in vivo modification of T cells through the addition of a specific chimeric receptor directed at a cancer cell target: complementing the interesting post by John Gordon that is attached. The explanation is developed as separate comments in 14 notes to the present and two references are added. https://lnkd.in/dwEKzZeM
#Immunotherapy | A #CAR Body Shop ๐ค | Generation of #CARTcells in vivo using #Lentiviral #Vectors displaying a Multi-Domain Fusion Ligand ๐ | Major Advance from Byoung Ryu & Co. at #BLOOD Online Now ๐ | #cancer | Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformative efficacy in treating B-cell malignancies. However, high cost and manufacturing complexities hinder their widespread use. T Here* to overcome these hurdles, Umoja Biopharma researchers have developed the VivoVecTM platform, a lentiviral vector capable of generating CAR T-cells in vivo. They describe the incorporation of T cell activation and costimulatory signals onto the surface of VivoVecTM particles (VVPs) in the form of a multi-domain fusion protein and show enhanced in vivo transduction and improved CAR-T cell antitumor functionality. Furthermore, in the absence of lymphodepleting chemotherapy, administration of VVPs into non-human primates resulted in the robust generation of anti-CD20 CAR T-cells and the complete depletion of B cells for more than 10 weeks. These data validate the VivoVecTM platform in a translationally relevant model and support its transition into human clinical testing, offering a paradigm shift in the field of CAR T-cell therapies. *https://lnkd.in/eNjvUPdX Celentyx Ltd Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady GRAPHICAL ABSTRACT
To view or add a comment, sign in
-